Dewpoint Therapeutics secures funding for DPTX3186 development
The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod
According to the agreements, MS Pharma will oversee the registration, marketing along with the distribution of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) throughout MENA. Polpharma Biologics will
This round of financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), with contributions from existing investors including Newpath Partners, OrbiMed, Euclidean Capital, Chugai Venture Fund,